These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8538932)

  • 1. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
    Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
    Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
    Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
    J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TrueFISP MR imaging to determine the influence of hemodialysis on the myocardial functional parameters in patients with terminal renal insufficiency].
    Kramer U; Wolf S; Fenchel M; Kraft A; Tomaschko K; Stauder N; Risler T; Claussen CD; Miller S
    Rofo; 2004 Mar; 176(3):350-6. PubMed ID: 15026948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
    Silberberg J; Racine N; Barre P; Sniderman AD
    Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
    Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Left ventricular hypertrophy in patients on hemodialysis: importance of anemia].
    Stojimirović B; Petrović D; Obrenović R
    Med Pregl; 2007; 60 Suppl 2():155-9. PubMed ID: 18928184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperthyroidism, therapy with erythropoietin, malnutrition and systolic function in hemodialysis: echocardiography study].
    Iannetti E; Carpinteri G; Vitale M; Squatrito R; Catalano D; Trovato GM
    Recenti Prog Med; 2000 Dec; 91(12):632-5. PubMed ID: 11194481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in left ventricular function and mass during serial investigations after valve replacement for aortic stenosis.
    Lund O; Erlandsen M
    J Heart Valve Dis; 2000 Jul; 9(4):583-93. PubMed ID: 10947054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could CAPD modulate the hemodynamic changes induced by rHuEPO treatment?
    Fernández A; Vega N; Hortal L; Jimenez F; Laraudogoitía E; Macía M; Plaza C; Perdomo M; Palop L
    Adv Perit Dial; 1992; 8():435-9. PubMed ID: 1361842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of left ventricular chamber stiffness at rest to exercise capacity in hypertrophic cardiomyopathy.
    Dumont CA; Monserrat L; Peteiro J; Soler R; Rodriguez E; Bouzas A; Fernández X; Pérez R; Bouzas B; Castro-Beiras A
    Am J Cardiol; 2007 May; 99(10):1454-7. PubMed ID: 17493479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis.
    Chung S; Song HC; Shin SJ; Ihm SH; Park CS; Kim HY; Yang CW; Kim YS; Choi EJ; Kim YK
    Hemodial Int; 2012 Apr; 16(2):181-7. PubMed ID: 22103889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalization of right ventricular performance and remodeling evaluated by magnetic resonance imaging at late follow-up of heart transplantation: relationship between function, exercise capacity and pulmonary vascular resistance.
    Bacal F; Pires PV; Moreira LF; Silva CP; Filho JR; Costa UM; Rosário-Neto MA; Avila VM; Cruz FD; Guimarães GV; Issa VS; Ferreira SA; Stolf N; Ramires JA; Bocchi E
    J Heart Lung Transplant; 2005 Dec; 24(12):2031-6. PubMed ID: 16364845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment.
    Jensen PB; Ekelund B; Nielsen FT; Baumbach L; Pedersen FB; Oxhøj H
    Clin Nephrol; 2000 Jan; 53(1):25-32. PubMed ID: 10661479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin.
    Löw I; Grützmacher P; Bergmann M; Schoeppe W
    Clin Nephrol; 1989 Jan; 31(1):26-30. PubMed ID: 2521587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac mortality prevention in uremic patients. Therapeutic strategies with particular attention to complete correction of renal anemia.
    Berweck S; Hennig L; Sternberg C; Dingerkus H; Ludat K; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S80-5. PubMed ID: 10746811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of blood pressure changes during hemodialysis on left ventricular systolic function].
    Kaźmierczak M; Grajek S; Kaźmierczak E; Minczykowski A; Czarnecki R; Siminiak T
    Pol Tyg Lek; 1993 Jan 18-25; 48(3-4):54-7. PubMed ID: 8361888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.